Oxford Immunotec Global PLC (NASDAQ:OXFD) had its price objective trimmed by Piper Jaffray Companies from $26.00 to $19.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has an overweight rating on the stock.

Several other analysts have also issued reports on the company. Zacks Investment Research lowered Oxford Immunotec Global PLC from a hold rating to a sell rating in a research note on Wednesday, August 30th. Cowen and Company reaffirmed a buy rating and issued a $22.00 target price on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. Finally, BTIG Research started coverage on Oxford Immunotec Global PLC in a research note on Thursday, September 28th. They issued a buy rating and a $21.00 target price for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Oxford Immunotec Global PLC currently has an average rating of Hold and a consensus price target of $19.75.

Shares of Oxford Immunotec Global PLC (NASDAQ OXFD) remained flat at $$13.25 on Tuesday. The company had a trading volume of 191,572 shares, compared to its average volume of 144,654. The company has a quick ratio of 2.51, a current ratio of 4.72 and a debt-to-equity ratio of 0.38.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). The business had revenue of $26.10 million during the quarter, compared to analyst estimates of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 38.42% and a negative net margin of 45.74%. Oxford Immunotec Global PLC’s revenue for the quarter was up 35.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.29) earnings per share. analysts predict that Oxford Immunotec Global PLC will post -2.11 earnings per share for the current fiscal year.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/oxford-immunotec-global-plc-oxfd-pt-lowered-to-19-00-at-piper-jaffray-companies/1676852.html.

In other news, COO Peter Edwardson sold 22,371 shares of the stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $17.70, for a total transaction of $395,966.70. Following the completion of the sale, the chief operating officer now owns 102,644 shares of the company’s stock, valued at $1,816,798.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,110 shares of company stock valued at $1,563,564. Insiders own 8.11% of the company’s stock.

Several large investors have recently added to or reduced their stakes in OXFD. Nationwide Fund Advisors boosted its stake in shares of Oxford Immunotec Global PLC by 1.9% during the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock valued at $213,000 after purchasing an additional 254 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Oxford Immunotec Global PLC by 129.2% during the first quarter. Wells Fargo & Company MN now owns 65,937 shares of the company’s stock valued at $1,021,000 after purchasing an additional 37,163 shares during the period. American International Group Inc. boosted its stake in shares of Oxford Immunotec Global PLC by 7.1% during the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after purchasing an additional 904 shares during the period. Teachers Advisors LLC boosted its stake in shares of Oxford Immunotec Global PLC by 15.7% during the first quarter. Teachers Advisors LLC now owns 46,200 shares of the company’s stock valued at $716,000 after purchasing an additional 6,268 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Oxford Immunotec Global PLC by 97.8% during the first quarter. Renaissance Technologies LLC now owns 363,300 shares of the company’s stock valued at $5,628,000 after purchasing an additional 179,600 shares during the period. 79.21% of the stock is owned by hedge funds and other institutional investors.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

The Fly

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.